Stigmasterol represses the development of prostate cancer by inducing p53 protein expression, while inhibiting p21 and p27 protein expression [20] and induces an increase of proapoptotic signals (BAX and p53) while decreasing antiapoptotic signals (Bcl-2) in liver cancer. Here, BCL2 is linked to prostate carcinoma.